Elmar Jaeckel

6.2k total citations · 1 hit paper
153 papers, 4.0k citations indexed

About

Elmar Jaeckel is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Elmar Jaeckel has authored 153 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hepatology, 63 papers in Epidemiology and 52 papers in Surgery. Recurrent topics in Elmar Jaeckel's work include Liver Disease Diagnosis and Treatment (58 papers), Liver Diseases and Immunity (40 papers) and Liver Disease and Transplantation (33 papers). Elmar Jaeckel is often cited by papers focused on Liver Disease Diagnosis and Treatment (58 papers), Liver Diseases and Immunity (40 papers) and Liver Disease and Transplantation (33 papers). Elmar Jaeckel collaborates with scholars based in Germany, Canada and United States. Elmar Jaeckel's co-authors include Michael P. Manns, Harald von Boehmer, Matthias Hardtke‐Wolenski, Heiner Wedemeyer, Richard Taubert, Fatih Noyan, Markus Cornberg, Teresa Santantonio, Christian Trautwein and Manfred Dietrich and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Elmar Jaeckel

146 papers receiving 3.9k citations

Hit Papers

Treatment of Acute Hepatitis C with Interferon Alfa-2b 2001 2026 2009 2017 2001 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of Acute Hepatitis C with Interferon Alfa-2b
    2001 516 citations Elmar Jaeckel, Markus Cornberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elmar Jaeckel Germany 30 1.6k 1.4k 1.4k 828 676 153 4.0k
Ye Htun Oo United Kingdom 37 2.0k 1.3× 1.9k 1.3× 1.7k 1.2× 772 0.9× 297 0.4× 110 4.3k
Kumiko Isse United States 34 851 0.5× 674 0.5× 824 0.6× 1.3k 1.6× 290 0.4× 70 3.0k
Yun Ma United Kingdom 37 3.0k 1.9× 2.5k 1.7× 1.1k 0.8× 884 1.1× 352 0.5× 73 4.3k
Dhanpat Jain United States 35 1.1k 0.7× 1.2k 0.9× 461 0.3× 1.3k 1.6× 400 0.6× 142 4.3k
Violet Esquenazi United States 32 424 0.3× 542 0.4× 735 0.5× 1.6k 2.0× 401 0.6× 153 3.5k
Pieter E. Zondervan Netherlands 36 2.6k 1.6× 2.8k 1.9× 393 0.3× 1.2k 1.5× 218 0.3× 142 4.7k
Giorgio Ballardini Italy 34 2.2k 1.4× 1.6k 1.1× 304 0.2× 760 0.9× 228 0.3× 93 3.3k
Charlotte Ryan United States 28 512 0.3× 687 0.5× 260 0.2× 803 1.0× 271 0.4× 73 2.8k
Pilar Barrera Netherlands 36 649 0.4× 690 0.5× 1.8k 1.3× 433 0.5× 372 0.6× 97 4.6k
Stuart M. Curbishley United Kingdom 21 979 0.6× 799 0.6× 847 0.6× 482 0.6× 146 0.2× 38 2.2k

Countries citing papers authored by Elmar Jaeckel

Since Specialization
Citations

This map shows the geographic impact of Elmar Jaeckel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elmar Jaeckel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elmar Jaeckel more than expected).

Fields of papers citing papers by Elmar Jaeckel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elmar Jaeckel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elmar Jaeckel. The network helps show where Elmar Jaeckel may publish in the future.

Co-authorship network of co-authors of Elmar Jaeckel

This figure shows the co-authorship network connecting the top 25 collaborators of Elmar Jaeckel. A scholar is included among the top collaborators of Elmar Jaeckel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elmar Jaeckel. Elmar Jaeckel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dywicki, Janine, Laura Elisa Buitrago‐Molina, Anna Baumann, et al.. (2025). From model to man: Understanding Tregs' dual role in MASLD. JHEP Reports. 7(12). 101619–101619. 1 indexed citations
2.
Li, Zhihao, Owen Jones, Luckshi Rajendran, et al.. (2025). Comparing outcomes of deceased-donor and living-donor liver transplants in patients with PVT. Liver Transplantation. 32(1). 55–64.
3.
Li, Zhihao, Owen Jones, Marco P. A. W. Claasen, et al.. (2024). Living Donor Availability Improves Patient Survival in a North American Center. Annals of Surgery. 283(2). 326–334. 3 indexed citations
4.
Rajendran, Luckshi, Zhihao Li, Woo Jin Choi, et al.. (2024). Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation. 109(4). 681–690. 4 indexed citations
5.
Rajendran, Luckshi, Won‐Jun Choi, Laura Aceituno-Mata, et al.. (2024). 183P Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Annals of Oncology. 35. S82–S83. 1 indexed citations
6.
Azhie, Amirhossein, Shiyi Chen, Wei Xu, et al.. (2024). Long-Term Survival of Canadian Liver Transplant Recipients Remains Stagnant— A Cohort Study on the Evolution of Cause-Specific Mortality. Digestive Diseases and Sciences. 70(2). 543–551. 1 indexed citations
7.
Chen, Shiyi, Wei Xu, Keyur Patel, et al.. (2023). Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis. Hepatology Communications. 7(8). 7 indexed citations
8.
Orchanian‐Cheff, Ani, et al.. (2023). A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis. Transplantation Direct. 9(11). e1547–e1547. 1 indexed citations
9.
Ytting, Henriette, Björn Hartleben, Heike Bantel, et al.. (2023). Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells. Hepatology Communications. 7(4). 2 indexed citations
10.
Ravens, Sarina, Immo Prinz, Laura Elisa Buitrago‐Molina, et al.. (2022). PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer. Liver Cancer. 12(2). 129–144. 9 indexed citations
11.
Zachou, Kalliopi, Simon Pape, Elmar Jaeckel, et al.. (2021). Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Reports. 3(4). 100321–100321. 27 indexed citations
12.
Engel, Bastian, Anne Höfer, Björn Hartleben, et al.. (2021). Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. American Journal of Transplantation. 22(2). 519–531. 19 indexed citations
13.
Pape, Simon, Tom J.G. Gevers, Jan Maarten Vrolijk, et al.. (2019). Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology. 17(10). 2068–2075.e2. 45 indexed citations
14.
Jaeckel, Elmar, et al.. (2019). 自己免疫性肝炎患者におけるプレドニソ(LO)NE投与量と寛解のチャンス【JST・京大機械翻訳】. Clinical Gastroenterology and Hepatology. 17(10). 2068–2075. 7 indexed citations
15.
Taubert, Richard, et al.. (2018). Novel therapeutic targets in autoimmune hepatitis. Journal of Autoimmunity. 95. 34–46. 19 indexed citations
16.
Pischke, Sven, A. Gisa, Torsten Witte, et al.. (2013). 1232 INCREASED HEV SEROPREVALENCE IN PATIENTS WITH AUTOIMMUNE HEPATITIS. Journal of Hepatology. 58. S500–S500. 7 indexed citations
17.
18.
Mederacke, Ingmar, Sandra Ciesek, R. Raupach, et al.. (2009). 333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY. Journal of Hepatology. 50. S129–S129. 3 indexed citations
19.
El‐Armouche, Ali, et al.. (2007). Long-term β-Adrenergic Stimulation Leads to Downregulation of Protein Phosphatase Inhibitor-1 in the Heart. European Journal of Heart Failure. 9(11). 1077–1080. 24 indexed citations
20.
Jaeckel, Elmar, Michael P. Manns, & Matthias von Herrath. (2002). Viruses and Diabetes. Annals of the New York Academy of Sciences. 958(1). 7–25. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ye Htun Oo Breakdown of academic impact, for papers by Kumiko Isse Breakdown of academic impact, for papers by Yun Ma Breakdown of academic impact, for papers by Dhanpat Jain Breakdown of academic impact, for papers by Violet Esquenazi Breakdown of academic impact, for papers by Pieter E. Zondervan Breakdown of academic impact, for papers by Giorgio Ballardini Breakdown of academic impact, for papers by Charlotte Ryan Breakdown of academic impact, for papers by Pilar Barrera Breakdown of academic impact, for papers by Stuart M. Curbishley
Rankless by CCL
2026